Latest Information Update: 25 Mar 2017
At a glance
- Originator Lundbeck A/S
- Class Antiparkinsonians
- Mechanism of Action Dopamine receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in Denmark
- 30 Oct 2009 Phase-I clinical trials in Parkinson's disease in Denmark (unspecified route)